Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

MHC heterogeneity and response of metastases to immunotherapy.

Cancer metastasis reviews - 1 Jun 2021

Algarra Ignacio, Garrido Federico, Garcia-Lora Angel M

Abstract excerpt

In recent years, immunotherapy has proven to be an effective treatment against cancer. Cytotoxic T lymphocytes perform an important role in this anti-tumor immune response, recognizing cancer cells as foreign, through the presentation of tumor antigens by MHC class I molecules. However, tumors and metastases develop escape mechanisms for evading this immunosurveillance and may lose the expression of these...

Topics

Join the communities discussing this publication.

Histocompatibility Antigens Class I
Immunotherapy
Neoplasm Metastasis
Neoplasms
Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33860434
DOI: 10.1007/s10555-021-09964-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MHC heterogeneity and response of metastases to immunotherapy.PMID 33860434Read ↗

Cancer immune escape: MHC expression in primary tumours versus metastasesSemantic proximity Read ↗

Altered MHC class I antigens in tumors.Semantic proximity Read ↗

MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.Semantic proximity Read ↗

Biological Consequences of MHC-II Expression by Tumor Cells in CancerSemantic proximity Read ↗

The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses.Semantic proximity Read ↗

Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implicationsSemantic proximity Read ↗

The HLA crossroad in tumor immunology.Semantic proximity Read ↗

Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype.Semantic proximity Read ↗

HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activationSemantic proximity Read ↗

MHC antigens and tumor escape from immune surveillance.Semantic proximity Read ↗

Biological heterogeneity of cancer: implication to therapy.Semantic proximity Read ↗

Role of altered expression of HLA class I molecules in cancer progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.